Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The arrangement, if consummated, would relate to the development and commercialization of PRX–110, or alidornase alfa, for the treatment of Pulmonary Sarcoidosis and related diseases.
Lead Product(s): Alidornase alfa
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PRX–110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Protalix BioTherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 23, 2020